Dexketoprofen Dosage According to Chronotherapy
Launched by UNIVERSIDAD COMPLUTENSE DE MADRID · Jan 3, 2022
Trial Information
Current as of June 10, 2025
Completed
Keywords
ClinConnect Summary
A randomized crossover split-mouth clinical trial will be performed. After third molar extractions, patients will be prescribed randomly in one side intake morning medication dosage while the contralateral side will be prescribed a night dosage. Moreover, a blood sample will be obtained to analyze the inflammatory profile.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Bilateral impacted lower third molar
- Exclusion Criteria:
- • NSAID allergic
- • Contraindication of surgery
About Universidad Complutense De Madrid
The Universidad Complutense de Madrid (UCM) is a prestigious academic institution renowned for its commitment to research and innovation in various fields, including health sciences. As a prominent sponsor of clinical trials, UCM leverages its extensive resources and expertise to advance medical knowledge and improve patient outcomes. The university fosters collaboration among researchers, clinicians, and industry partners, ensuring the highest standards of ethics and scientific rigor in its clinical research initiatives. UCM's dedication to education and research excellence positions it as a leader in the development of new therapeutic interventions and health solutions.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Madrid, , Spain
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials